Unusual side effects in patients with psoriatic erythroderma treated with etretinate (RO 10-9359)
Castel, T.; Castro, J.; Lecha, M.; Mascaró, J.M.
Medicina Cutanea Ibero-Latino-Americana 14(2): 83-86
1986
ISSN/ISBN: 0210-5187 PMID: 2943953 Document Number: 273468
The results of the treatment of psoriatic erythroderma are variable in different references. The authors describe the treatment of three patients and emphasize the immuno-modulatory action of etretinate on polymorphonuclears, monocytes and Langerhans cells and the possibility of an action on prostaglandins.
Document emailed within 1 workday
Related Documents
Mom, A.; Aresca, S.; Fuente, G.; Pecorini, V.; Pellerano, G.; Perez, V. 1982: Razoxane in the treatment of psoriatic patients resistant to or intolerant of PUVA, methotrexate and etretinate Acta Dermato-Venereologica 62(4): 357-358Lauharanta, J.; Salo, O.; Kanerva, L.; Lassus, A. 1982: The effect of etretinate on fibronectin in psoriatic skin Acta Dermato-Venereologica 62(4): 358-361
Calzavara-Pinton, P.G.; Carlino, A.; Manfredi, E.; Semeraro, F.; Zane, C.; De Panfilis, G. 1994: Ocular side effects of PUVA-treated patients refusing eye sun protection Acta Dermato-Venereologica. Supplementum 186: 164-165
Skripkin, I.K.; Korotkiĭ, N.G.; Butov, I.S.; Savkina, A.S.; Biriukov, A.V. 1982: Case of successful treatment, by a photochemotherapy method, of psoriatic erythroderma due to total ultraviolet irradiation Vestnik Dermatologii i Venerologii 9: 40-42
Altamura, A.C.; Buccio, M.; Colacurcio, F.; Colombo, G.; Terzi, A. 1986: Orphenadrine plasma levels and amelioration of extrapyramidal side effects in schizophrenic patients treated with haloperidol Acta Neurologica 8(1): 19-26
Lubach, D.; Kietzmann, M. 1988: Effects of treatment with dithranol, etretinate and a combination of dithranol and etretinate on epidermal metabolism and histology. Mouse tail assay Arzneimittel-Forschung 38(8): 1167-1170
Pander Maat, H.; Klaassen, R. 1996: The effect of the wording of information about side effects on patients' interpretation of reported side effects Nederlands Tijdschrift Voor Geneeskunde 140(8): 424-427
Alvarado Ibarra, M.L.; Borbolla Escoboza, J.R.; López-Hernández, M.A.; González-Avante, C.M.; FloresChapa, J.D.; Trueba Christy, E.; Anaya Cuellar, I. 1999: Neutrophil recovery time and adverse side effects in acute leukemia patients treated with intensive chemotherapy and concomitant G or GM-CSF Revista de Investigacion Clinica; Organo del Hospital de Enfermedades de la Nutricion 51(2): 77-80
Polano, M.K.; van der Rhee, H.J.; van der Schroeff, J.G. 1982: A three-year follow-up study of psoriasis patients treated with low dosages of etretinate orally and corticosteroids topically Acta Dermato-Venereologica 62(4): 361-364
Borbujo Martínez, J.M.; Casado Jiménez, M.; Garijo López, M.B.; Soto Melo, J. 1987: An unusual secondary effect of etretinate Medicina Clinica 89(13): 577
Ninane, J.; Mahieu, P.; Hassoun, A.; Goenen, M. 1978: Unusual side effects following administration of dipyrone and acetylsalicylic acid Acta Clinica Belgica 33(5): 292-295
Goh, C.L.; Khoo, L. 2004: Laser Doppler perfusion imaging (LDPI) and transepidermal water loss (TEWL) values in psoriatic lesions treated with narrow band UVB phototherapy. Dermal vascularity may be useful indicator of psoriatic activity Annals of the Academy of Medicine Singapore 33(1): 75-79
Majewski, S.; Wolska, H.; Jabłońska, S.; Wasik, M. 1989: Effects of systemic etretinate treatment on natural cytotoxicity, immune angiogenesis and neutrophil adherence in patients with various forms of psoriasis Archivum Immunologiae et Therapiae Experimentalis 37(3-4): 459-464
Belzunegui, J.; Intxausti, J.J.; De Dios, J.R.; López-Domínguez, L.; Queiro, R.; González, C.; Figueroa, M. 2001: Absence of pulmonary fibrosis in patients with psoriatic arthritis treated with weekly low-dose methotrexate Clinical and Experimental Rheumatology 19(6): 727-730
Chodorowska, G.; Czelej, D.; Juszkiewicz-Borowiec, M.; Pietrzak, A.; Wojnowska, D.; Krasowska, D. 1999: Selected cytokines and acute phase proteins in psoriatic patients treated with cyclosporin A or Re-PUVA methods Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina 54: 173-180
Halkier-Sørensen, L. 1988: Sexual dysfunction in a patient treated with etretinate Acta Dermato-Venereologica 68(1): 90-91
Cattaneo, M.; Betti, R.; Lodi, A.; Boidi, G. 1986: A case of Hallopeau's acrodermatitis continua treated with etretinate Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale Societa Italiana di Dermatologia e Sifilografia 121(2): 143-145
Salvarani, C.; Lo Scocco, G.; Macchioni, P.; Cremonesi, T.; Rossi, F.; Mantovani, W.; Battistel, B.; Bisighini, G.; Portioli, I. 1995: Prevalence of psoriatic arthritis in Italian psoriatic patients Journal of Rheumatology 22(8): 1499-1503
Bordier, C.; Flechet, M.L.; Thomine, E.; Lauret, P. 1984: Rupture of atrophic striae during pustular psoriasis treated with etretinate (Tigason) Annales de Dermatologie et de Venereologie 111(10): 929-931
Britton, S. 2013: Vaccines must have a minimal amount of side effects. Serious side effects threatens public trust Lakartidningen 110(16): 816